Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2019.197 | The effects of mindfulness-based intervention for loneliness on older adults: a randomised controlled trial |
Prof. WONG Samuel 黃仰山 |
| 2019.610 | Community eHealth Care Project | Prof. WONG Samuel |
| 2020.571 | Robotic Technology and Digital Health Applications in Primary Care | Prof. WONG Samuel |
| 2018.165 | Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong | Prof. WONG Samuel |
| 2010.537 | Evaluation study of stakeholders satisfaction of Patient Empowerment Programme (PEP) | Prof. WONG Samuel |
| 2010.536 | Evaluation study of stakeholders satisfaction of Nurse and Allied Health Programme (NAHC) | Prof. WONG Samuel |
| 2010.535 | Evaluation study of stakeholders satisfaction of Shared Care Programme (SCP) | Prof WONG Samuel |
| 2017.489 | Loving-kindness and Compassion Meditation: Exploring and evaluating its effectiveness on improving psychological well-being among healthcare workers in Hong Kong |
Prof. WONG Samuel 黃仰山 |
| 2012.474 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Prof. WONG Samuel |
| 2022.343 | Effectiveness of a New Approach in Stroke Upper Limb Rehabilitation with Shortened Fugl-Meyer Assessment Classification: A Randomized Controlled Trial |
Miss WONG Sally Hiu Lam 黃曉嵐 |
| 2020.290 | Biodegradable Magnesium Screws in Elbow Fracture Fixation: Clinical Case Series |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2018.602 | Promoting to tackle sarcopenia by combined elastic-band resistance exercise or vibration treatment with hydroxylmethylbutyrate (HMB) supplement for older people | Prof. WONG Ronald Man Yeung |
| 2018.584 | Vibration Therapy as an Intervention for Enhancing Trochanteric Hip Fracture Healing in Elderly Patients: A Randomized Double-Blinded, Placebo-Controlled Clinical Trial |
Dr. WONG Ronald Man Yeung 黄文揚 |
| 2018.192 | Necrotizing fasciitis induced by Vibrio Vulnificus in Patients without Marine Contact in Hong Kong | Dr. WONG Ronald Man Yeung |
| 2018.354 | Promotion in the Early Management of Knee Osteoarthritis in Community-dwelling Elderlies – “A New Community-based Vibration Therapy Program to Prevent Falls, Strengthen Muscle and Relief Pain” |
Dr. WONG Ronald Man Yeung 黃文揚 |
| 2019.579 | Comparative Persistence With Prolia® and Weekly Alendronate in 6 Asia-Pacific countries: a Prospective Observational Study |
Dr. WONG Ronald Man Yeung 黃文揚 |
| 2018.415 | Vibration Therapy as a Rehabilitation Intervention for Postural Training and Fall Prevention after Distal Radius Fracture in Elderly Patients: A Randomized Controlled Trial | Dr. WONG Ronald Man Yeung |
| 2019.202 | Imminent Fracture in Hong Kong | Prof. WONG Ronald Man Yeung |
| 2019.227 | Prevention of Imminent Fragility Fractures: A Call to Action in Hong Kong | Prof WONG Ronald Man Yeung |
| 2021.384 | Prevalence of Ostersarcopenia in Fragility Fracture Patients |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2023.401 | RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial | Prof. WONG Ronald Man Yeung |
| 2021.622 | Fracture Liaison Services For Osteoporotic Fracture |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2021.008 | The Composition of Gut Microbiota in Patients with Sarcopenia and Osteoporosis |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2021.478 | A multicentre retrospective study on the clinical and radiological features, and outcome of surgical treatment in Atypical Femoral Fractures in Hong Kong |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2022.555 | RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial | Prof. WONG Ronald Man Yeung |
| 2022.079 | Sarcopenia in Hip Fracture Patients |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2021.488 | Detection of Clinically Silent Vertebral Fractures with Vertebral Fracture Assessment on a Fracture Liaison Service in a Chinese Population |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2022.256 | Artificial Intelligence in Detection of Vertebral Compression Fracture |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2017.447 | Vibration Therapy as a Rehabilitation Intervention for Postural Training and Fall Prevention after Distal Radius Fracture in Elderly Patients: A Randomized Controlled Trial | Dr. WONG Ronald Man Yeung |
| 2016.391 | A study to evaluate the effectiveness of a structured patient education on patient discharge in Department of Medicine and Therapeutics, Prince of Wales Hospital |
Ms. WONG Rebecca Yee Man 黃綺文 |
| 2009.087 | Peer Leaders Accelated Training Initiative to Unlash Potential of mentorship (PLATINUM) Program: A feasibility study on a train-the-trainer course on peer support for people with type 2 diabetes | Ms WONG Rebecca Y M |
| 2012.406 | A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | Dr. Wong Raymond Siu-Ming |
| 2010.159 | A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura(ITP) | Dr. WONG Raymond Siu Ming |
| 2019.158 | An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.160 | A Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.225 | A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2016.463 | A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.652 | A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations (BELLWAVE-008) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.567 | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.641 | A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.347 | Molecular study of myelofibrosis with next generation sequencing to identify prognostic markers and to evaluate applicability of prognostic models in Chinese population |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.493 | A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.392 | Molecular study of essential thrombocythaemia with next generation sequencing to identify prognostic markers in Chinese population | Dr. WONG Raymond Siu Ming |
| 2021.151 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NOT PREVIOUSLY TREATED WITH COMPLEMENT INHIBITORS |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.655 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2021.152 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT INHIBITORS |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.182 | A Randomized, Open-Label, Two-Arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.710 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2020.692 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITANT JAK2 INHIBITOR THERAPY AND WHO REQUIRE RED BLOOD CELL TRANSFUSIONS The “INDEPENDENCE” Trial |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.411 | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) |
Dr. WONG Raymond Siu Ming 王紹明 |
Page 28 of 264.